Literature DB >> 954835

Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid.

M Chignard, B Vargaftig.   

Abstract

Dog platelets are refractory to aggregation by arachidonic acid (AA) but generate an unstable activity that aggregates rabbit platelets. Formation of this activity is inhibited by indomethacin, by the peroxide scavenging enzyme catalase, by two chelating agents that bind Cu+ and Cu2+ ions, by the -SH agent dithiothreitol and is stimulated by cysteine. Agitation of dog platelets is followed by spontaneous aggregation and uncovers aggregation by AA, which is blocked by indomethacin. Neither indomethacin nor apyrase prevent spontaneous aggregation, ruling out both activation of prostaglandin synthetase and leakage of ADP as possible explanations. Complexation of plasma Ca2+ by citrate as an explanation for refractoriness to AA was ruled out by replacing citrate with heparin. Dog platelets are also refractory to PGH2 formed from AA by the cyclo oxygenase component of prostaglandin synthetase. Aggregation of rabbit platelets by PGH2 is not inhibited by indomethacin, by catalase, by dithiothreitol or by metal chelating agents and is not potentiated by cysteine. This confirms that the reagents act before PGH2 is formed. Aggregating activity generated by dog platelets is probably due to an unstable lipoperoxide whose generation involves mechanisms similar to those responsible for aggregation of rabbit platelets, since similar antagonists block both processes.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 954835     DOI: 10.1016/0014-2999(76)90195-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Comparative pharmacology of arachidonic acid in various animal species: platelet-mediated and platelet-indipendent reactions [proceedings].

Authors:  B B Vargaftig; J Lefort; M Chignard
Journal:  Agents Actions       Date:  1978-01

2.  Biotransformation of arachidonic acid in the circulation of the dog [proceedings].

Authors:  G J Dusting; S Moncada; K M Mullane; J R Vane
Journal:  Br J Pharmacol       Date:  1978-06       Impact factor: 8.739

3.  Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.

Authors:  D J Fitzgerald; J Doran; E Jackson; G A FitzGerald
Journal:  J Clin Invest       Date:  1986-02       Impact factor: 14.808

4.  Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis.

Authors:  D J Fitzgerald; J Fragetta; G A FitzGerald
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

5.  Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction.

Authors:  G J Johnson; L A Leis; P C Dunlop
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

6.  Platelet-leukocyte interactions following arterial endothelial injury.

Authors:  N B Ratliff; J M Gerrard; J G White
Journal:  Am J Pathol       Date:  1979-08       Impact factor: 4.307

7.  The effect of oral phenylbutazone on whole blood platelet aggregation in the dog.

Authors:  M L Jackson; G P Searcy; D W Olexson
Journal:  Can J Comp Med       Date:  1985-07

8.  Lack of thromboxane A2 involvement in the arrhythmias occurring during acute myocardial ischemia in dogs.

Authors:  S E Burke; M J Antonaccio; A M Lefer
Journal:  Basic Res Cardiol       Date:  1982 Jul-Aug       Impact factor: 17.165

9.  The roles of prostaglandin endoperoxides, thromboxane A2 and adenosine diphosphate in collagen-induced aggregation in man and the rat.

Authors:  H Emms; G P Lewis
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.